For immediate release | 13 May 2024 |
Gooch & Housego PLC
("G&H" or the "Company" or the "Group")
Notification of Half Year Results
Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components and systems, will announce its results for the six months ended 31 March 2024 on Tuesday 4 June 2024.
A meeting for analysts will be held at 10.30am on 4 June 2024 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. To register attendance, please contact Buchanan at G&H@buchanan.uk.com.
A live audio webcast of the meeting will be available via the following link: https://stream.buchanan.uk.com/broadcast/663c7e38f309b09a38728804
Following the meeting, a recording of the webcast will be made available for replay at the Group's website at https://gandh.com/investors/.
For further information please contact:
Charlie Peppiatt, Chief Executive Officer Chris Jewell, Chief Financial Officer | Gooch & Housego PLC | +44 (0) 1460 256440 |
|
| |
Mark Court / Sophie Wills / Abigail Gilchrist | Buchanan | +44 (0) 20 7466 5000 |
|
| |
Christopher Baird / David Anderson | Investec Bank plc | +44 (0) 20 7597 5970 |
Notes to editors
Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.